New Frontiers in Tackling Hypertension Across America

A Drug for the Resistant

Baxdrostat, a novel aldosterone synthase inhibitor, cut systolic pressure dramatically in patients who failed standard regimens, offering hope for the 1.3 billion worldwide with uncontrolled hypertension.

Innovative Therapies

Researchers reported a cell‑based therapy that safely reverses pulmonary arterial hypertension, while another study identified a brainstem region that may drive resistant blood‑pressure spikes, pointing to future neuromodulatory options.

Proven Team‑Based Models

A NIH‑backed trial showed that low‑cost, team‑oriented care—home monitoring, health coaching and protocol‑driven treatment—lowered systolic pressure by over 15 mm Hg in high‑risk U.S. patients. Similar results were echoed in a STAT‑reported study of federally qualified health centers serving underserved communities.

What Comes Next

Regulators are reviewing Baxdrostat, and larger trials will test the brain‑targeted approach. Meanwhile, health‑system leaders are scaling team‑based models to close the gap between prescription and control.